COPYRIGHT. Advancing to Insulin Replacement Therapy: When, Why, and How? Update in Internal Medicine December 5, Richard S.
|
|
- Jessica Dalton
- 6 years ago
- Views:
Transcription
1 Advancing to Insulin Replacement Therapy: When, Why, and How? Update in Internal Medicine December 5, 2016 Richard S. Beaser, MD Medical Director, Professional Education Joslin Diabetes Center Associate Professor of Medicine Harvard Medical School
2 Key Messages Insulin Therapy Insulin is a highly effective diabetes treatment Individualize treatment goals and regimens Consider pathophysiology, self-care, and safety Use pattern assessment to adjust dosing and advance therapy To treat Type 2 Diabetes, consider the advancement sequence recommended by nationally-recognized guidelines from basal alone to basal-bolus insulin therapy Recognize and address patient, provider, and practice-level barriers to insulin therapy Some treatment services should be provided in the practice, others obtained by consultation
3 Aggressive Control of Diabetes: Goals of Treatment ADA AACE A1C (%) < Preprandial glucose (mg/dl) < hour postprandial glucose (mg/dl) < 180 < 140 A1C is gold standard measure of diabetes control over previous 2 3 months American Diabetes Association. Diabetes Care. 2016;39(suppl 1):S39-S46. Garber AJ, Abrahamson MA, Barzilay JI, et al. Endocrine Practice 2016;22:
4 Key Parameters Reflecting Glycemic Control A1C Preprandial glucose levels Fasting Sequentially through the day Postprandial glucose levels Absolute level Level relative to pre-prandial
5 Individualizing A1C Targets for People with T2DM Most 6.0% Intensive Less Intensive 7.0% Least Intensive 8.0% Low Moderate Few/Mild Risk from Hypoglycemia and other adverse drug effects High Disease Duration Newly Diagnosed Long-Standing Not usually modifiable Life Expectancy Long Absent Absent Few/Mild Short Important Comorbidities Severe Established Vascular Complications Severe Highly Motivated, Adherent, Excellent Self- Care Capacities Readily available Patient attitude/expected treatment effort Less motivated, Non-adherent, Poor Self-Care Capacities, Resources and Support System Limited Potentially modifiable ADA, EASD Position Statement. Diabetes Care 2015;38;
6 Physiologic Insulin Secretion: 24-hour Profile Insulin (µu/ml) Glucose (mg/dl) Basal insulin Breakfast Lunch Dinner AM PM Time of day Basal glucose
7 Relative Contribution of FPG and PPG to Overall Hyperglycemia Depending on A1C Quintiles Contribution (%) Postprandial glucose Fasting glucose 0 < >10.2 n=58 n=58 n=58 n=58 n=58 A1C (%) Quintiles Monnier L et al. Diabetes Care. 2003;26:
8 When to Consider Insulin in a person with Type 2 Diabetes When a combination of non-insulin antidiabetes medications are unable to achieve A1C target High fasting or postprandial glycemia Unacceptable side effects of other medications Advanced hepatic or renal disease Special considerations (steroids, infection, pregnancy) Hyperglycemia in a hospitalized patient Severely uncontrolled diabetes* * Random Glucose > 300 mg/dl, A1C > 10%, Ketonuria, Symptomatic polyuria/polydipsia, weight loss Nathan DM, et al. Diabetes Care. 2009; volume 32, Inzucchi SE, et al. Diabetes Care. 2012;35(6): ADA Diabetes Care. 2015:38(Suppl 1):S41-S48.
9 Type 2 Diabetes and Need for Insulin UKPDS: at 6 years, more than 50% of patients (newly diagnosed at start of study) need insulin to reach target (FPG 6.0 mmol/l) Patients Requiring Insulin (%) Years from Randomization FPG = fasting plasma glucose Wright A, et al. Diabetes Care. 2002;25:
10 Types of Insulin Rapid-acting: - Inhaled human insulin Rapid-acting analogs: - Aspart, Glulisine, Lispro (U-100 or U-200) Short-acting insulin: Regular (soluble) Intermediate-acting insulin: NPH Human insulin 70/30: - Premix NPH/regular Premixed Analogs: - Insulin lispro mix 75/25, 50/50 - Biphasic insulin aspart 70/ Time (hours) Adapted from Hirsch I. N Engl J Med. 2005;352: Long-acting insulin: - Detemir, Glargine - Glargine U Degludec U-100 or U-200
11 Insulin to provide Basal and Bolus Coverage Basal insulin Replicates normal basal insulin secretion in the fasting and postabsorptive state which regulates hepatic glucose production and limits lipolysis Controls fasting and premeal glucose levels A good basal insulin should have a low risk of hypoglycemia Bolus insulin Replicates acute insulin secretion at mealtimes to both suppress liver glucose production and increase uptake of glucose in peripheral tissues Blunts rise in glucose after meals
12 TDD = Total Daily Dose Reprinted with permission from American Association of Clinical Endocrinologists 2016 AACE. Garber, AJ Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive type 2 diabetes management algorithm Endocr Pract. 2016;22:
13 Desired Characteristics of Replacement Basal Insulin Mimics natural pancreatic basal insulin secretory pattern No distinct peak effect Continued effect over 24 hours Minimizes risk of nocturnal hypoglycemia Administered once daily for optimal patient adherence Reliable absorption pattern
14 Weight Gain with Detemir vs NPH A1C (%) *P< Detemir NPH Weeks +6.2 lb +2.6 lb* At least 70% of subjects in each group achieved A1C 7% Average Body Weight (lb) Hermansen K et al. Diabetes Care. 2006;29:
15 Glargine vs NPH in Treat-To-Target No Difference in A1C but Reduced Hypoglycemia with Glargine A1C 9.0% 8.5% 8.0% 7.5% 7.0% 6.5% 6.0% 756 Patients with Type 2 Diabetes on 1 or 2 Oral Agents Glycemic Control Over Time Glargine NPH Weeks of Treatment Cumulative Number of Events (Documented PG 56 mg/dl) Hypoglycemia Hypoglycemia Reduced 42-46% Time (days) PG = plasma glucose Adapted from Riddle et al. Diabetes Care. 2003;26:
16 Treat-to-Target Trial: Timing and Frequency of Hypoglycemia Hypoglycemia by Time of Day Hypoglycemia Episodes (PG 72 mg/dl) Basal insulin * * * * Insulin glargine NPH insulin B L D * * * 20:00 22:00 24:00 2:00 4:00 6:00 8:00 10:00 12:00 14:00 16:00 18:00 20:00 * P <0.05 (between treatment). PG = plasma-referenced glucose. Time Riddle MC, et al. Diabetes Care. 2003;26:
17 Pharmacodynamics of Glargine U-300 versus U-100 GIR (mg/kg -1 min -1 )* SC Injection Time (hours) U U/kg -1 U U/kg -1 The U-300 glargine has a flatter more prolonged effect The time it takes for 50% of the effect of a single injection U-100 = 12.1 hours U-300 = 16.7 hours U U/kg -1 U U/kg -1 GIR = glucose infusion rate. Shiramoto M et al. Diab Obes Metab. 2015;17:
18 U-300 Insulin Glargine U-300 insulin glargine offers a smaller depot surface area leading to a reduced rate of absorption Provides a flatter and prolonged pharmacokinetic and pharmacodynamic profiles and more consistency Half-life is ~23 hours Associated with less hypoglycemia especially nocturnal hypoglycemia Only available in pens 300 U/mL, 1.5 ml Max dose per shot is 80 units with current pen Garber AJ. Diabetes Obesity Metab 2014;16: Owens DR, et al. Diabetes Metab Res Rev. 2014;30(2): Steinstraesser A, et al. Diabetes Obes Metab. 2014;16: Accessed September 4, 2015
19 Comparison of Glargine U-300 to Glargine U-100 Similar reduction in A1C & FPG Less nocturnal hypoglycemia Likely need 15% higher dose Ritzel R, et al. Diabetes, Obesity and Metabolism 2015;17:
20 Pharmacodynamics of Degludec Glucose Lowering Effect on Day 6 (mg/kg/min) Ideg 0.8 U/kg Ideg 0.6 U/kg Ideg 0.4 U/kg Time since Injection (hours) desb30 insulin acylated (16-c fatty acid chain) at LysB29 Half-life is ~25.4 hours, duration > 42 h Josse RG and Woo V. Diabetes Obes Metab. 2013;15(12): Garber AJ. Diabetes Obesity Metab 2014; 16: Heise et al. Diabetes Obes Metab 2012;14:944 50
21 Variability of Effect Variability in effects of an insulin can cause unexplainable variations in glucose control from day to day Insulin Within Subject Variability (CV% of AUC GIR) NPH 68 Glargine U Detemir 27 Glargine U Degludec 20 Adapted from: Rossetti P, et al. Diabetes Obes Metab, 2014;16: ; Becker RHA, et al. Diabetes Obes Metab, 2015;17:261-7
22 Insulin Titration: Options when control is not adequate using one daily injection of basal insulin Basal plus GLP-1 agonist OR Switch to a premixed insulin analog Divide dose in half and give twice daily (before breakfast and dinner) OR Basal Plus Basal insulin plus a short-acting insulin analogue before the largest meal of the day OR Switch to basal-bolus regimen 23
23 Exenatide BID Added to Insulin Glargine Outcome PBO EXENATIDE BID P- Value Δ FPG (mg/dl) a Δ Insulin dose (U/d) b Δ Weight (kg) <.001 Hypoglycemia c (events/patient-y) Discontinuation due to AEs (% of patients) <.01 a Baseline FPG: 149 and 142 mg/dl for PBO and EXN BID groups, respectively. b Baseline insulin: 47.4 and 49.5 U/d for PBO and EXN BID groups, respectively. c 1 reported event of major hypoglycemia (PBO group). EXN BID or PBO Added to GLAR 30-week trial (N = 259) A1C Change (%) GLAR + EXN BID P < GLAR + PBO Adapted from Buse JB et al. Ann Intern Med. 2011;154:
24 Comparison of GLP-1 RA s vs. Prandial Insulin when used with Basal Insulin A1C, % LIRAGLUTIDE QD 1, a P =.0024 ASPART QD 1, a Noninferior EXENATIDE BID 2, b LISPRO TID Outcome: LIRA vs. ASPART 1 EXEN BID vs. LISPRO 2 ALBIG vs. LISPRO 3 Δ Weight, kg 2.8* * 0.7* 0.8 Hypoglycemia d 1.0* Nausea, % LIRA > ASP, first 2 wks Basal Insulin used Degludec Glargine Glargine Duration / n 26 weeks / weeks / weeks / 566 2,3, b, c Noninferior ALBIGLUTIDE QW 3, c a Added to DEG (26 wk; N = 177) b Added to GLAR (30 wk; N = 637). c Added to GLAR (26 wk; N = 566). d Rates of severe hypoglycemia were low across groups * P < Mathieu et al. Diabetes Obes Metab. 2014;16: Diamant et al. Diabetes Care. 2014;37: Rosenstock et al. Diabetes Care. 2014;37: Eli Lilly and Co. Trulicity (dulaglutide) prescribing information US FDA. Drugs@FDA.
25 Adding GLP-1-RA vs. bolus insulin to optimized basal insulin Rx program for Type 2 diabetes Diamant M et al Diabetes Care 2014;37:
26 Combination Basal Insulin GLP-1 RA Fixed Ratio Formulations DEG-LIRA 1,a,b DEG 1,b LIRA 1,b GLAR-LIXI 2,a,c GLAR 2,c Δ A1C, % Δ BW, KG A1C < 7%, %: d 65 d Noninferior to DEG; Superior to LIRA d 0.5 e -3.0 d d Superior to GLAR Ø 3 severe hypoglycemic episodes per group Ø Lower rate of hypoglycemia for LIRA vs DEG or DEG-LIRA (overall and nocturnal) 1 Ø Lower rate of hypoglycemia for GLAR-LIXI than for GLAR (overall) 2,e Current GLP-1 RAs should not be mixed with or injected adjacent to insulin 3 DEG=Degludec; Lira=liraglutide GLAR=Glargine Lixi=Lixisenatide 1. Gough et al. Lancet Diabetes Endocrinol. 2014;2: Rosenstock et al. Diabetologia. 2014;57(suppl 1) [abstract 241]. 3. US FDA. Drugs@FDA. DA. a Not US FDA approved. b 26-week open-label, treat-to-target RCT; N = 1663 (insulin naïve). c 24-week open-label, treat-to-target RCT; N = 323 (insulin naïve). d P <.001 vs DEG-LIRA; e P <.001 vs GLAR-LIXI.
27 Role for Premixed Insulin Advantages Easy (no mixing, single product, pens avail.) Covers insulin requirements through most of day Disadvantages Not physiologic Less Flexible: requires consistent meal/exercise pattern, and cannot titrate individual insulins unless custom mixed insulin is used Nocturnal hypoglycemia (presupper NPH) Fasting hyperglycemia (presupper NPH wears off) Higher A1C (realistic goal of 8%) Janka HU et al. Diabetes Care. 2005;28: Fritsche et al. Diab Obes Metab. 2010;12(2): ADA, EASD Position Statement. Diabetes Care 2012;35;
28 The Study: Achievement of HbA1c Targets With Premixed Insulin Analog Therapy Subjects (Cumulative %) ITT population* (n = 100) Mean baseline A1C level: 8.6% % (AACE) <7.0% (ADA) 77 QD BID TID *All patients enrolled in the trial. Garber AJ, et al. Diabetes Obes Metab. 2006;8(1):
29 INITIATE: Basal Analog vs Premixed Analog A1C Level (%) Change in A1C Level From Baseline to Study End Baseline Endpoint 9.8% 7.4% Insulin Glargine + OADs P < % 2.8% 9.7% Raskin P, Allen E, Hollander P, et al. Diabetes Care. 2005;28(2): % Biphasic Insulin Aspart 70/30 Episodes per Patient Year Documented Hypoglycemic Episodes (<56 mg/dl) 0.7 Insulin Glargine + OADs P < Biphasic Insulin Aspart 70/30 Total units = with glargine plus OADs vs with premixed insulin OAD = Oral antihypertlycemic agent 30
30 Rate of Hypoglycemic Event Occurrence Description of Event (Adjusted Rate) SMBG < 70 mg/dl (with symptoms) SMBG < 50 mg/dl (with symptoms) Insulin Glargine/ Insulin Glulisine-3 (Events/Patient- Year; n=194) Insulin Glargine/ Insulin Glulisine-1 (Events/Patient- Year; n=194) Premixed Insulin Aspart 70/30 (Events/Patient- Year; n=194) 7.23 (0.99) a 7.11 (0.99) a (1.68) 0.89 (0.15) b 0.83 (0.15) b 1.91 (0.31) SMBG < 36 mg/dl 0.15 (0.03) 0.10 (0.03) a 0.23 (0.05) Severe hypoglycemia c 0.17 (0.05) 0.10 (0.03) 0.17 (0.05) Serious hypoglycemia d N/A N/A N/A Insulin glargine/insulin glulisine-3 and insulin glargine/insulin glulisine-1 groups had lower hypoglycemic event rates than premixed insulin aspart 70/30 group a P<0.01 vs premixed insulin aspart 70/30 b P vs premixed insulin aspart 70/30 c Hypoglycemic events requiring assistance and either BG <36 mg/dl or prompt response to countermeasures d Hypoglycemia with coma/loss of consciousness or seizure/convulsion. N/A = not applicable; SMBG = self-monitored blood glucose. Riddle et al. ADA Scientific Sessions
31 Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes Fulcher, GR, et al. Diabetes Care 2014:37:
32 Clinical Features of Rapid-Acting Analogues: Aspart, Glulisine, and Lispro Administration immediately prior to meals Faster onset of action matches timing of carbohydrate absorption Limits postprandial hyperglycemic peaks Shorter duration of activity Reduced risk of late postprandial hypoglycemia Frequently can have late postprandial hyperglycemia Glulisine can be given after meals if needed * * Garg S et al. American Diabetes Association 64 th Scientific Sessions; June 4-8, 2004; Orlando, FL; Abstract 530-P
33 Fewer Nocturnal Hypoglycemic Events in Patients Treated with Aspart vs Regular Human Insulin Major Nocturnal Hypoglycemic Events per Patient-Year % Aspart P= Regular Human Insulin Adapted from Heller SR et al. Diabet Med. 2004;21:
34 Concentrated Insulin Lispro U-200 vs U-100 Pharmacodynamics of Lispro U-100 & U-200 are comparable Glucose Infusion Rate (mg/min) Insulin Lispro 100 Units/ml Insulin Lispro 200 Units/ml Time From Dose (h) (Mean SE Data) de la Peña A et al. Clin Pharmacol Drug Dev 2016;5:69-75
35 Inhaled Insulin Technosphere insulin (TI) marketed as Afrezza, recently FDA approved Indicated for adults with type 1 or 2 diabetes, in combination with longacting insulin. Ultra-rapid-acting insulin: Onset minutes, peak 60 minutes, duration hr RSS = Rapid-acting analog GIR = Glucose infusion rate Afrezza Package insert; Santos Cavaiola T, Edelman S. Clin Ther. 2014;36:
36 Inhaled Insulin: Limitations and Contraindications Limitations: Inhaled insulin is not a substitute for long-acting insulin. Not recommended for the treatment of diabetic ketoacidosis Not recommended in patients who smoke or who have stopped smoking in last 6 months. Contraindications: During episodes of hypoglycemia In patients who have chronic lung disease such as COPD or asthma inologicandmetabolicdrugsadvisorycommittee/ucm pdf
37 Adding Bolus Insulin Consider adding prandial (mealtime) insulin in about 3 6 months if: A1C is elevated Significant postprandial glucose excursions occur (> 180 mg/dl) There are significant drops in glucose between meals or overnight as the basal insulin dose is increased Likely needed if the total daily insulin dose exceeds 0.5 Units/kg/day. ADA, EASD Position Statement. Diabetes Care 2015;38;
38 Adding Bolus Insulin Add prandial insulin before meal with largest glucose excursion (>180 mg/dl) or the meal with the largest CHO content. Other meals can be covered subsequently. Alternatively start with coverage of all three meals at once. TDD: U/kg; 50/50 basal/prandial Antihyperglycemic medications: Generally, stop insulin secretagogues (SU, DPP-4 inhibitors, glinides) Reduce or stop TZD s Based on: Nathan DM, et al. Diabetes Care. 2009;32: ADA, EASD Position Statement. Diabetes Care 2015;38; AACE/ACE Comprehensive Diabetes Management Algorithm, Endocr Pract. 2015;21(No. 4) TDD=Total daily dose SU = Sulfonlyurea
39 STEPwise Study Do you add injection at the largest meal or the one with the highest postprandial elevation? Overall reduction in HbA1C of 1.2% was achieved with the addition of prandial insulin. Greatest HbA1C reductions were achieved with the first and second bolus injections. Glycemic improvement comparable in both groups. Number of hypoglycemic episodes increased with increasing number of prandial injections. Basal-bolus treatment can be introduced in a more patient-friendly approach, using simple stepwise addition of prandial insulin. Meneghini, et al. Endocr Pract. 2011;17:
40 Adding Prandial Insulin to Basal Therapy Further Improves HbA1C Decrease in A1C (%) Glargine ± OHA (n=534) * Glargine ± OHA + OD Prandial (n=534) Glargine ± OHA + BD Prandial (n=178) Glargine ± OHA + > BD Prandial (n=193) * * * * p<0.001 for baseline to endpoint change: OHA = oral antihyperglycemic agent; OD=once daily; BD=twice daily Davies M et al Diabetes Obes Metab May;10(5):
41 Physiologic Insulin Regimens with basal insulin plus rapid-acting insulin dosing before each meal Checking blood glucose 4 to 6 times a day CHO counting or consistent CHO Intake Premeal insulin dosing by algorithmic scale or, preferably, carbohydrate counting Surveillance and risk for hypoglycemia Record keeping: Monitoring rather than just checking
42 Sample Insulin Adjustment Algorithm: Premeal Rapid-Acting and Bedtime Basal Insulin An option for determining premeal insulin doses if carbohydrate counting is not possible Rapid-Acting Insulin BLOOD GLUCOSE BREAKFAST LUNCH SUPPER BED 0 70* OVER *Treat with food first, retest, then use algorithmic dose. Basal Insulin 20 *Treat with food first, retest, then use algorithmic dose.
43 Carbohydrate Counting, Matching and Postprandial Control Two factors primarily govern the dose of premeal insulin: Grams of carbohydrate Correction doses if premeal hyperglycemia is present Two calculations are useful for initial dosing: Carbohydrate coverage: Total daily insulin dose (TDD) divided into 500 gives the approximate number of carb grams that 1 unit of rapid acting insulin will cover. Correction dose: Divide the TDD into Usually initially target a glucose of 120 mg/dl
44 Carbohydrate Counting, Matching and Postprandial Control: Example Ø Calculating a carbohydrate (CHO) counting insulin dosing program for a total daily insulin dose of 50 units: Basal insulin: 25 units daily at bedtime Premeal coverage based on CHO intake: Total daily insulin dose (TDD) = 50 units 500/50 = 10 Give 1 unit of premeal rapid-acting insulin for every 10 grams of carbohydrate to be consumed. Correction dose: 1500/50 = 30 Give an extra unit of rapid-acting premeal insulin for every 30 points above 120 mg/dl
45 Simple Algorithm vs Carbohydrate Counting For Mealtime Insulin Adjustment A1C % Insulin dose (U/kg/d) Simple Algorithm: 1.9 Carb Counting: 1.7 P < Baseline Simple Algorithm Group Carb-Count Group Weight gain (kg): Simple Algorithm: 3.6 Carb Counting: 2.4 P = 0.06 Bergenstal R, Johnson M, Powers MA et al. Diabetes Care. 2008;31:
46 Glucose Monitoring No one should perform a single glucose test unless he or she knows what to do with the result! There is a difference between glucose checking (testing) and glucose monitoring Individualize monitoring schedule Record-keeping is of crucial importance to the monitoring process
47 External Insulin Pump Using Rapid Acting Insulin Insulin Effect Insulin Bolus Doses B L S Snack HS B Meals Insulin Basal
48 Suggested Sequence for Assessment of Glycemic Patterns Fasting value General premeal and bedtime values and trends throughout the day Postprandial values absolute levels Relative change, pre- to postprandial glycemic levels à Also, continually monitor nocturnal glycemia
49 Continuous Glucose Monitoring Provides a More Comprehensive Picture of the Patterns Glucose (mg/dl) Fingerstick Blood Glucoses (Type 1) Glucose measurement Insulin bolus Target Range 0 12:00 am 6:00 am 12:00 6:00 pm 12:00 am
50 CGM Software Report
51 Factors Influencing Therapeutic Choices Ø Medical needs and treatment goals A1C level and distance from target Postprandial glycemia Ø Safety Ø Need for flexibility in treatment program Ø Patient issues with respect to insulin use Intellect and judgment Psychosocial and cultural considerations Physical capabilities and limitations Other medical conditions and issues relating to use of other non-insulin medications
52 Patient Barriers to Insulin Initiation Ø Needing insulin represents a personal failure Describe the natural progression of type 2 diabetes and the inevitability of the need for insulin Do not use insulin as a threat Ø Insulin is not effective Many patients do not believe insulin is effective Match insulin use to goals that patients can see: Glycemic patterns, symptoms Ø Insulin causes complications Many patients saw relatives/friends start insulin in the context of bad events happening Provide supportive education Ø Impact on lifestyle Perceived causes: Injection schedule, hypoglycemia Provide supportive education Insulin pens Adapted from Funnell MM. Clinical Diabetes. 2007;25(1):36-38.
53 Patient Barriers to Insulin Initiation Ø Injections are painful Perceive that they are the same as inoculations or other painful injection experiences Compare to glucose checking Demonstration injection Discuss needle size; use of pens Ø Fear of hypoglycemia Observing problems in others Education focusing on advantages of newer insulins, hypoglycemia avoidance, appropriate goal setting Ø Insulin causes weight gain Acknowledge the possibility Discuss strategies to avoid: Dietitian, CHO counting Ø Cost Acknowledge/compare cost for insulin vs. DM Meds Explore strategies to reduce costs Adapted from Funnell MM. Clinical Diabetes. 2007;25(1):36-38.
54 Physician Barriers to Insulin Initiation Ø Systems deficiencies Recognizing indications, impact of treatment: EMR reminders Educational support: Train office staff; identify/develop working relationship with additional educational resources Ø Provider education about insulin Optimize your own knowledge and skills Ø Concern about hypoglycemia Similar issues to patients Set individualized goals and design appropriate Rx Provide supportive education Ø Weight gain Use dietitians, physiologic insulin programs Ø Unease in dealing with patient emotions/barriers Develop strategies and practice them! Adapted from Funnell MM. Clinical Diabetes. 2007;25(1): Derr RL, et al. Diabetes Spectrum. 2007; 20(3):
55 A Stepwise Perspective on Insulin Treatment Ability to identify people for whom insulin is indicated and discuss this need with them Capability or identified referral resources to oversee insulin treatment initiation and support Ability to teach insulin use: Techniques Knowledge and Skills for self-management Spectrum of programs, from basal to pumps Ability to identify people for whom the current program is inadequate and advancement of therapy is indicated Troubleshooting Referral management
56 A Stepwise Perspective on Insulin Treatment Ability to identify people for whom insulin is indicated and discuss this need with them Capability or identified referral resources to oversee insulin treatment initiation and support Ability to teach insulin use: Techniques Knowledge and Skills for self-management Spectrum of programs, from basal to pumps Ability to identify people for whom the current program is inadequate and advancement of therapy is indicated Troubleshooting Referral management
57 Take-Away Messages Treatment goals, program design, and monitoring recommendations must be individualized Monitoring of glycemic patterns is a key tool to guide therapeutic decisions Basal-bolus regimens require more injections but provide better insulin coverage and glycemic control Patient, provider, and practice systems barriers to insulin therapy must be recognized and addressed Self-assess office capabilities in the context of insulin treatment support
58 Insulin is a remedy for the wise and not the foolish, be they patients or doctors. Everyone knows it requires brains to live long with diabetes, but to use insulin successfully requires more brains. Elliott P. Joslin, MD, ScD Diabetic Manual, 1959
UKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationEvolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk
Evolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk Harvard/Joslin Primary Care Congress for Cardiometabolic Health 2013 Richard S. Beaser, MD Medical Executive
More informationNatural History of Type 2 Diabetes
Key Points About Insulin to Discuss Today We should be using insulin earlier in the natural history of type 2 diabetes How early and how do we know when to start insulin? Barriers to insulin therapy Goals
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationIndividualizing Therapy int2dm With Insulin
Individualizing Therapy int2dm With Insulin Etie Moghissi, MD, FACP, FACE Clinical Associate Professor University of California, Los Angeles Los Angeles, California OBJECTIVES: At the conclusion of this
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationProgressive Loss of β-cell Function in T2DM
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of November 2015. The content and views presented in this educational activity are those of
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationOptimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes
Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Philip Raskin, MD Professor of Medicine The University of Texas, Southwestern Medical Center NAMCP Spring
More informationnocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded
Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,
More information5/16/2018. Insulin Update: New and Emerging Insulins. Disclosures to Participants. Learning Objectives
Insulin Update: New and Emerging Insulins Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA Disclosures to
More informationBasal & GLP-1 Fixed Combination Use
Basal & GLP-1 Fixed Combination Use Michelle M. Mangual, MD Diplomate of the American board of Internal Medicine and Endocrinology, Diabetes and Metabolism San Juan City hospital Learning Objectives o
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More informationThese Aren t Your Average Rookies: A Primer on New and Emerging Insulins. Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP
These Aren t Your Average Rookies: A Primer on New and Emerging Insulins Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP Disclosures Eli Lilly & Company: Advisory board member Boehringer Ingelheim: Advisory
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More information9/8/2016. Faculty. Examining the Role of Long-Acting Insulin within the Physiologic Approach to Glucose Control. Disclosures. Learning Objectives
9/8/21 Faculty Examining the Role of Long-Acting within the Physiologic Approach to Glucose Control Dace Trence, MD, FACE Professor, Division of Metabolism, Endocrinology and Nutrition Director, Diabetes
More informationBrigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol
Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients
More informationMixed Insulins Pick Me
Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing
More informationWhat to Do After Basal Insulin
BasalINSULIN What to Do After Basal Insulin 3 Treatment Strategies for Type 2 Diabetes These strategies can help you optimize glucose control in your patient with type 2 diabetes when basal insulin alone
More informationT2DM and Need for Insulin. Insulin Pharmacokinetics. When To Start Insulin in T2DM. FDA-approved Insulins for Subcutaneous Injection
Plasma Insulin Levels Patients Requiring Insulin (%) Effective Use of Insulin in the Primary Care Practice: Insulin Therapy Initiation, Intensification, and the Insulinizing Complex Patients with T2DM:
More informationWhat's New in Insulin Related Therapies 2018
What's New in Insulin Related Therapies 2018 James Lenhard, MD (JLenhard@ChristianaCare.org) Section Chief, Endocrinology and Metabolism Christiana Care Health System Newark, DE Disclosures Speaker:Eli
More informationWhat s New? An Antihyperglycemic Medications Update
What s New? An Antihyperglycemic Medications Update WADE 2016 Annual Conference Josh Neumiller, PharmD, CDE, FASCP Associate Professor Department of Pharmacotherapy Washington State University Disclosures
More informationInjectable Agents for Type 2 Diabetes. Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017
Injectable Agents for Type 2 Diabetes Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017 Financial Disclosures Sanofi speaker honoraria No other relevant financial disclosures Injectable
More informationADA and AACE Glycemic Targets
ADA and AACE Glycemic Targets HbA1C target should be individualized based on a number of factors including: Age Life expectancy Comorbidities Duration of diabetes Risk of hypoglycemia Patient motivation
More informationINSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital
INSULIN THERAPY Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 3 Sep. 2013 Case Somsak is a 64-year-old man was diagnosed with T2DM, HT, and dyslipidemia 9 years ago. No history of hypoglycemia
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More informationObjectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment
Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Judy Thomas, MSN, FNP-BC Holt and Walton, Rheumatology and Endocrinology Objectives Upon completion of this session you will be better
More informationIndividualising Insulin Regimens: Premixed or basal plus/bolus?
Individualising Insulin Regimens: Premixed or basal plus/bolus? Dr. Ted Wu Director, Diabetes Centre, Hospital Sydney, Australia Turkey, April 2015 Centre of Health Professional Education Optimising insulin
More informationYour Chart Review Data. Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine
Your Chart Review Data Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine Participation 243 registered for the program 98 have completed the Practice
More informationFaculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives
Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management Faculty Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Professor of Pharmacy Practice Associate Director of Experiential
More informationNew Drug Evaluation: Insulin degludec/aspart, subcutaneous injection
New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand
More informationSession 3: Insulin Strategies for Primary Care Providers: Addressing a Core Defect in Diabetes Learning Objectives
Session 3: Insulin Strategies for Primary Care Providers: Addressing a Core Defect in Diabetes Learning Objectives 1. Design strategies to help patients overcome cultural barriers to using insulin, and
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationStarting and Helping People with Type 2 Diabetes on Insulin
Starting and Helping People with Type 2 Diabetes on Insulin Elaine Cooke, BSc(Pharm), RPh, CDE Pharmacist and Certified Diabetes Educator Maple Ridge, BC Objectives After attending this session, participants
More informationInjecting Insulin into Out Patient Practice
Injecting Insulin into Out Patient Practice Kathleen Colleran, MD Associate Professor UNMHSC 4/22/10 Overview Natural history of Type 2 diabetes Reasons clinicians are reluctant to start insulin therapy
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationHouston, TX. March 12th, 2015
March 12th, 215 George R. Brown Conven on Center Houston, TX P F Dace L. Trence, MD, FACE Professor, Department of Medicine Director, Endocrine Fellowship Program Director, Diabetes Care Center University
More informationInsulin Intensification: A Patient-Centered Approach
MARTIN J. ABRAHAMSON, MD Harvard Medical School, Boston, MA Insulin Intensification: A Patient-Centered Approach Dr Abrahamson is associate professor of medicine at Harvard Medical School and medical director
More informationComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary
Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationJune 5th, Pennsylvania Convention Center 1101 Arch St Philadelphia, PA 19107
June 5th, 214 Pennsylvania Convention Center 111 Arch St Philadelphia, PA 1917 Dace Trence, MD, FACE Director, Diabetes Care Center Professor, Division of Metabolism, Endocrinology and Nutrition University
More informationFaculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI
Activity Overview In this case-based webcast, meet Jackie, a 62-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 9.2%, and she is taking 2 oral agents and basal insulin; however,
More informationUpdate on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy
Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy Jerry Meece, BPharm, CDE, FACA, FAADE Director of Clinical Services Plaza Pharmacy and Wellness Center Gainesville,
More informationPosition Statement of ADA / EASD 2012
Management of Hyperglycemia in Type2 Diabetes: A Patient- Centered Approach Position Statement of ADA / EASD 2012 Cause of : Type 2 diabetes Cardiovascular disorders Blindness End-stage renal failure Amputations
More informationInsulin Therapy Management. Insulin Therapy
Insulin Therapy Management Insulin Therapy Contents Insulin and its effect on glycemic control Physiology of insulin secretion Insulin pharmacokinetics and regimens Insulin dose adjustment for pregnancy
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationThe New Age of Insulin: Exploring the Latest Trends in Insulin Therapy. The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy
The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Director of Experiential Education Associate Professor of Pharmacy Practice Midwestern
More informationDiabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items
Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Hayley A. Miller, MD Physician, Internal Medicine, Diabetes and Metabolism, Sandy Clinic, Intermountain Healthcare Objectives:
More informationAdvances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D
Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies Module D 1 Learning Objectives Apply the principles of the comprehensive diabetes algorithms to patients with
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationIndividualizing Therapy int2dm With Insulin
Individualizing Therapy int2dm With Insulin Etie Moghissi, MD, FACP, FACE Clinical Associate Professor University of California, Los Angeles Los Angeles, California OBJECTIVES: At the conclusion of this
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationAPPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
More informationInsulin Therapies for T2DM
Insulin Therapies for T2DM Defects in T2DM Decreased insulin secretion Inefficient glucose uptake (skeletal muscles) Increased hepatic glucose production Decreased incretin effect Increased glucagon secretion
More informationIDegAsp provides simple intensification without the addition of another insulin injection and simple delivery system
CASE REPORT Diabetes Management IDegAsp provides simple intensification without the addition of another insulin injection and simple delivery system Shizuka Kaneko*, Youhei Ueda, Yumiko Tahara ABSTRACT
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationFrancesca Porcellati
XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia
More informationDrug List. Drug List (cont.) Objectives. Case 1 Bruce. Presenter Disclosure Information
1:15 :3 PM GLP-1 Receptor Agonists and Basal Insulin Combination: A Complementary Strategy for Type Diabetes Treatment Intensification SPEAKERS Vivian Fonseca, MD Dace Trence, MD, FACE Presenter Disclosure
More informationIndividualizing Therapy in T2DM With Insulin
Developed by the Institute for Individualizing Therapy in TDM With Insulin Davida F Kruger, MSN, APN-BC, BC-ADM Certified Nurse Practitioner Division of Endocrinology, Diabetes, and Bone and Mineral Disorders
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationMYTH VS FACT #1: GLP-1 RECEPTOR AGONISTS SHOULD BE RESERVED FOR PATIENTS WITH LONG-STANDING T2DM
15 mins for presentation & ARS MYTH VS FACT #1: GLP-1 RECEPTOR AGONISTS SHOULD BE RESERVED FOR PATIENTS WITH LONG-STANDING T2DM Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University
More informationPramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon
Pramlintide & Weight Diane M Karl MD The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Conflict of Interest Speakers Bureau: Amylin Pharmaceuticals Consultant: sanofi-aventis Grant
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) June 2017 Review: June 2020 (earlier if required see recommendations) Bulletin 255: Insulin aspart New Formulation - Fiasp JPC Recommendations:
More informationEmerging Challenges in Primary Care: Safely Achieving Goals in Type 2 Diabetes (T2D): The Role of Concentrated and Long-Acting Insulins
Emerging Challenges in Primary Care: 2018 Safely Achieving Goals in Type 2 Diabetes (T2D): The Role of Concentrated and Long-Acting Insulins 1 Faculty Rodolfo J. Galindo, MD Assistant Professor of Medicine
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationCurrent Clinical Practice Guideline for Diabetes Management
Current Clinical Practice Guideline for Diabetes Management Chaicharn Deerochanawong M.D. Professor of Medicine, i Rangsit Medical University it Diabetes and Endocrinology Unit Department of Medicine Rajavithi
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationLET S TALK INSULIN THE BASICS
LET S TALK INSULIN THE BASICS AUTHOR S DISCLOSURES Contracted for program development for Lifescan Canada Speaker for Lifescan, Lilly, BI, Consultant for Lilly, Janssen, Novo Nordisk, Lifescan Canada OBJECTIVES
More informationUse of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials
primary care diabetes 10 (2016) 51 59 Contents lists available at ScienceDirect Primary Care Diabetes journal homepage: http://www.elsevier.com/locate/pcd Original research Use of a basal-plus insulin
More informationAkio Ohta, Kaori Arai, Ami Nishine, Yoshiyuki Sada, Hiroyuki Kato, Hisashi Fukuda, Shiko Asai, Yoshio Nagai, Takuyuki Katabami and Yasushi Tanaka
Endocrine Journal 2013, 60 (2), 173-177 Or i g i n a l Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial
More informationWhat s My Line? Identifying the Role of New Ultralong- Acting Insulins for the Treatment of T2DM
What s My Line? Identifying the Role of New Ultralong- Acting Insulins for the Treatment of TDM Learning Objectives. Compare the pharmacodynamics and therapeutic characteristics of ultralong-acting basal
More informationMANAGEMENT OF DIABETES IN PREGNANCY
MANAGEMENT OF DIABETES IN PREGNANCY Ministry of Health Malaysia Malaysian Endocrine & Metabolic Society Perinatal Society of Malaysia Family Medicine Specialists Association of Malaysia Academy of Medicine
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationDrug List. Drug List (cont d) Objectives. Case and Initial CME Questions. Presenter Disclosure Information
:3 :5 PM How to Select and Initiate Insulin Therapy in the Type Diabetes Patient SPEAKERS Intekhab Ahmed, MD, FACE, FACP Felice Caldarella, MD, FACE, FACP, CDE Presenter Disclosure Information The following
More informationTransition of Care in Hospitalized Patients with Hyperglycemia and Diabetes
Transition of Care in Hospitalized Patients with Hyperglycemia and Diabetes Critically ill patients in the ICU Hospital Non-ICU Settings Home Guillermo E Umpierrez, MD, FACP, FACE Professor of Medicine
More informationDiabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)
Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) 9501366-011 20110401 Objectives Understand the need for insulin pumps and CGMS in managing
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationProviding Stability to an Unstable Disease
Basal Insulin Therapy Providing Stability to an Unstable Disease Thomas A. Hughes, M.D. Professor of Medicine - Retired Division of Endocrinology, Metabolism, and Diabetes University of Tennessee Health
More informationLearning Objectives. Are you ready for more insulin formulations?
Are you ready for more insulin formulations? Shara Elrod, PharmD, BCACP, BCGP Learning Objectives Review pharmacology and dosing of new insulin formulations Compare and contrast new insulin formulations
More informationObjectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17
Objectives Compare and contrast currently available products. Navigating New s Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Diabetes Center Determine the factors
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationLearning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C
UPDATES IN TYPE 2 DIABETES David Doriguzzi, PA-C Learning Objectives Upon completion of this educational activity, the participant should be able to: Overcome barriers and attitudes that limit Clinician/Patient
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationRole of Insulin Analogs in
Role of Insulin Analogs in Type 2 Diabetes Supported by an educational grant from Novo Nordisk Inc. This program is supported by an educational grant from Novo Nordisk Inc. It has been accredited by the
More information6/5/18. Emerging Challenges in Primary Care: Safely Achieving Goals in Type 2 Diabetes (T2D): The Role of Concentrated and Long- Acting Insulins
Emerging Challenges in Primary Care: 218 Safely Achieving Goals in Type 2 Diabetes (T2D): The Role of Concentrated and Long- Acting Insulins Faculty Rodolfo J. Galindo, MD Assistant Professor of Medicine
More informationRole of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD
Role of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD International Diabetes Center and Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More information